<DOC>
	<DOC>NCT00113594</DOC>
	<brief_summary>The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender, origin, and smoking status on olanzapine pharmacokinetics in adolescents with schizophrenia or bipolar I disorder. This study will also assess the safety of olanzapine delivered orally.</brief_summary>
	<brief_title>Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Male or female patients, 13 through 17 years of age (must not have reached their 18th birthday prior to Visit 1). Female patients must not be pregnant or nursing. Patient and patient's parent/authorized legal representative must have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must have given informed consent. Patient must have a previously documented diagnosis of schizophrenia or bipolar I according to the DSMIVTR, and either confirmed previously by KSADSPL or be confirmed by KSADSPL at Visit 1. Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or bipolar I disorder. Patients are not allowed into the study if they currently meet the criteria for the depressed phase of bipolar disorder or are diagnosed with Bipolar II Disorder.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>